ライフサイエンスコーパス: pharmacodynamics

1 gnitude and duration of response to therapy (pharmacodynamics).

2 in part B (to assess safety and longer-term pharmacodynamics).

3 exosomes to intercellular drug transfer and pharmacodynamics.

4 ndin exhibiting distinctive pharmacokinetics/pharmacodynamics.

5 y, antitumor efficacy, pharmacokinetics, and pharmacodynamics.

6 acokinetic profile for assessment of in vivo pharmacodynamics.

7 c disturbance per se is unrelated to altered pharmacodynamics.

8 se is related to altered pharmacokinetics or pharmacodynamics.

9 icles provided improved pharmacokinetics and pharmacodynamics.

10 acology of AMG 416 showed readily reversible pharmacodynamics.

11 unds impacting on their pharmacokinetics and pharmacodynamics.

12 ed pharmacokinetics, antitumor activity, and pharmacodynamics.

13 d an overall response, pharmacokinetics, and pharmacodynamics.

14 t of imaging biomarkers to monitor metabolic pharmacodynamics.

15 ing behaviour, indicating dose dependency of pharmacodynamics.

16 itaxel release (extent and rate) and in vivo pharmacodynamics.

17 iability in clopidogrel pharmacokinetics and pharmacodynamics.

18 o enhance active ingredient pharmacology and pharmacodynamics.

19 le of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics.

20 ore a critical step in the prediction of its pharmacodynamics.

21 th antileukemic drug pharmacokinetics and/or pharmacodynamics.

22 owever, this increases the complexity of the pharmacodynamics.

23 ion of the conditions governing the observed pharmacodynamics.

24 micronutrients on drug pharmacokinetics and pharmacodynamics.

25 ule biodistribution, target interactions and pharmacodynamics.

26 nfirm efficacy and further define safety and pharmacodynamics.

27 both intended and unintended, that comprise pharmacodynamics.

28 iable means for quantification of paclitaxel pharmacodynamics.

29 results in great changes in pharmacology and pharmacodynamics.

30 ude understanding of mechanism of action and pharmacodynamics.

31 d improving bacteriocin pharmacokinetics and pharmacodynamics.

32 model accounts for drug pharmacokinetics and pharmacodynamics.

33 recapitulating clinical pharmacokinetics and pharmacodynamics.

34 eir assembly, stability, immunogenicity, and pharmacodynamics.

35 orbidities, and altered pharmacokinetics and pharmacodynamics.

36 for understanding their pharmacokinetics and pharmacodynamics.

37 y and optimizing antibiotic pharmacokinetics/pharmacodynamics.

38 0%), efficacy (45%), pharmacokinetics (28%), pharmacodynamics (23%), and patient enrichment (14%) wer

39 were evaluable for both pharmacokinetics and pharmacodynamics (50%).

40 dual variation in anastrozole metabolism and pharmacodynamics among patients treated with the approve

41 Differences in pharmacokinetics and pharmacodynamics among statins lead to diverse biologica

42 ood, Sehgal et al report on the clinical and pharmacodynamics analysis of pomalidomide dosing strateg

43 study was to evaluate the pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the first s

44 murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimu

45 evaluates the safety, pharmacokinetics, and pharmacodynamics and defines the recommended phase II do

46 with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autorad

47 traightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time abov

48 tolide field focusing on differentiating the pharmacodynamics and especially the toxicology of the ma

49 riteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated.

50 ontribute to interactions between cell-based pharmacodynamics and in vivo pharmacokinetics that defin

51 n, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and

52 d multiple drug interactions that affect its pharmacodynamics and metabolism.

53 Assessment of safety, pharmacodynamics and nasal allergic reactivity following

54 t, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supp

55 ase2 inhibitor that possesses both favorable pharmacodynamics and pharmacokinetic (PK) parameters, in

56 ns, and fail to fully capture cytotoxic drug pharmacodynamics and pharmacokinetic variability in obes

57 nd neurodevelopmental delay; however, animal pharmacodynamics and pharmacokinetics do not directly co

58 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

59 However, improvement of the drug's pharmacodynamics and pharmacokinetics is desirable.

60 ate the role of ECMO, including studying the pharmacodynamics and pharmacokinetics of patients receiv

61 , however, little in-depth discussion of the pharmacodynamics and pharmacokinetics of the sedation ag

62 , we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and

63 al drawbacks with such peptides include poor pharmacodynamics and potential scrambling of the disulfi

64 cules within condensates contributes to drug pharmacodynamics and that further understanding of this

65 We emphasize the diversity in pharmacodynamics and toxicity of the macrolides and keto

66 ion half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with b

67 ssed safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of ARN-509 in m

68 and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398,

69 tives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of var

70 ely estimating the correct pharmacokinetics, pharmacodynamics, and drug interaction effects.

71 luded safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score i

72 We assessed the safety, pharmacokinetics, pharmacodynamics, and efficacy of lumacaftor and ivacaft

73 rial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor c

74 uate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized

75 rial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a

76 We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor

77 part B (to assess safety, pharmacokinetics, pharmacodynamics, and efficacy).

78 o characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the reco

79 ounds with improved selectivity, appropriate pharmacodynamics, and efficacy.

80 CV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles.

81 to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.

82 cidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate.

83 o inform on different drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the ab

84 dy to evaluate the safety, pharmacokinetics, pharmacodynamics, and potency of i.v. administrations in

85 imum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy wer

86 were safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.

87 the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mavorixafo

88 ing drug pharmacokinetics, measuring therapy pharmacodynamics, and providing a marker of therapeutic

89 We determined the safety, pharmacokinetics, pharmacodynamics, and recommended phase II dose of MK-87

90 and to assess its safety, pharmacokinetics, pharmacodynamics, and response rate in individuals with

91 arameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these par

92 tudies of biodistribution, pharmacokinetics, pharmacodynamics, and toxicity as well as scale-up manuf

93 To investigate BBB penetration, pharmacodynamics, and tumor retention kinetics of an ago

94 dynamics with antibody pharmacokinetics and pharmacodynamics, and will be generally applicable to fo

95 ndence, during physiologic activity, blocker pharmacodynamics are largely indistinguishable and large

96 SC) administration of nanochelators improves pharmacodynamics, as evidenced by a 7-fold increase in e

97 rations (pharmacokinetics) and drug actions (pharmacodynamics), available data from clinical trials,

98 se of physiologically based pharmacokinetic /pharmacodynamics-based approaches to forward and reverse

99 acokinetics (ABCG2, AHR, POR and CYP1A2) and pharmacodynamics (BDNF and SLC6A4) of caffeine.

100 employ conservative designs that incorporate pharmacodynamics/biomarker monitoring.

101 Sex differences in pharmacokinetics and pharmacodynamics characterize many drugs and contribute

102 antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profi

103 Our aim was to examine pharmacodynamics (colonic transit, bowel function) and p

104 iable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective asse

105 Pharmacokinetics-pharmacodynamics data show a steady-state concentration

106 The pharmacokinetics/pharmacodynamics data were used to identify model parame

107 24h or continuously worn for 4 days, and the pharmacodynamics effect of changes in the intraocular pr

108 developed a computational model of cisplatin pharmacodynamics following EBUS-TBNI.

109 ed understanding of the pharmacokinetics and pharmacodynamics for current and future antimicrobials i

110 ible with live, primary cells and can report pharmacodynamics for drug action on an intended target,

111 As pharmacodynamics for the approved dose are optimized onl

112 ors sought to study the pharmacokinetics and pharmacodynamics for ticagrelor 60 mg compared with 90 m

113 cokinetics, lung tissue pharmacokinetics and pharmacodynamics for two first line anti-TB antibiotics.

114 Indications of CPT pharmacodynamics from tumor biomarkers such as carbonic

115 cell, IC(50,free) = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat m

116 l evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopi

117 quantification of antibody accumulation and pharmacodynamics in brain tumors, offering a holistic ap

118 netics, safety, and efficacy in children and pharmacodynamics in individuals naive to antiretroviral

119 ing alterations in drug pharmacokinetics and pharmacodynamics in intensive care unit patients.

120 We examined pharmacodynamics in the tg2576 APPtg mouse with the prio

121 or activity; exploratory objectives included pharmacodynamics in timed paired tumor biopsies.

122 showed because of a better pharmacokinetics/pharmacodynamics index.

123 However, pharmacodynamics indicated a sustained mean occupancy of

124 d uptake of siRNA into the cell and improved pharmacodynamics inside the cell.

125 ween lipid structure/configuration and siRNA pharmacodynamics is unclear.

126 vel time-series study of drug effects (i.e., pharmacodynamics) is critical for understanding mechanis

127 Despite indistinguishable synaptic pharmacodynamics, ketamine provided significantly greate

128 real-time screening technologies to identify pharmacodynamics/-kinetics of single and combined drugs

129 rum pharmacokinetics (HVTN 104) and in vitro pharmacodynamics (LANL CATNAP database).

130 but differences in underlying aetiology and pharmacodynamics might differentially affect response to

131 The computational pharmacokinetics/pharmacodynamics model can be generalized to predict who

132 gically based computational pharmacokinetics/pharmacodynamics model was constructed to simulate the r

133 e-dose adjustment protocols, pharmacokinetic/pharmacodynamics modeling and international normalizatio

134 Dose-response curves followed exponential pharmacodynamics models for calcium chloride (EC50 1.8 m

135 risk for suboptimal drug concentrations and pharmacodynamics must be considered.

136 This study aims to describe the pharmacodynamics of a fluid challenge over a 10-minute p

137 therapy, however, is limited by the unknown pharmacodynamics of a replicating agent, as well as the

138 study investigated the safety, efficacy, and pharmacodynamics of a selective BTK inhibitor acalabruti

139 significant role in the pharmacokinetics and pharmacodynamics of a variety of drugs.

140 PET will be useful for the study of in vivo pharmacodynamics of Abl PKI molecular therapy in humans.

141 the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.

142 safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with sympto

143 on should center on the pharmacokinetics and pharmacodynamics of agents in an attempt to ameliorate p

144 nique insights into the pharmacokinetics and pharmacodynamics of agents that modulate c-Met activity

145 ide unique insight into pharmacokinetics and pharmacodynamics of agents that modulate EGFR activity,

146 factors that affect the pharmacokinetics and pharmacodynamics of anesthetic agents in the obese popul

147 isms in genes related to pharmacokinetics or pharmacodynamics of antileukemic agents, drug metabolism

148 Pharmacokinetics/pharmacodynamics of antimicrobial agents, differences am

149 nificant impacts on the pharmacokinetics and pharmacodynamics of artemether-lumefantrine treatment.

150 0263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in patients with schizophren

151 safety, tolerability, pharmacokinetics, and pharmacodynamics of avoralstat.

152 iminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific

153 -tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carfilzomib administered as a 30-min

154 assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine

155 or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants:

156 Is) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel.

157 he purpose of this study was to document the pharmacodynamics of CO2 for MBF using prospective end-ti

158 tudies identify a novel process by which the pharmacodynamics of cocaine are derived in vivo, and thu

159 oroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine the

160 safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acu

161 The pharmacodynamics of Cyto-012 and wt BoNT/A have similar

162 is of the antiviral effects, toxicities, and pharmacodynamics of different variants of cardiac glycos

163 irst article describing the pharmacokinetics/pharmacodynamics of doripenem solely in critically ill p

164 udies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical

165 velop an experimental system to evaluate the pharmacodynamics of dual phage-drug therapy.

166 aluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040.

167 designed to assess safety, tolerability, and pharmacodynamics of FBS0701, a novel oral chelator, in a

168 We characterized the mechanism and pharmacodynamics of five structurally distinct inhibitor

169 clearance, alters both pharmacokinetics and pharmacodynamics of furosemide in acute kidney injury, a

170 safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincri

171 rapeutic applications aimed at improving the pharmacodynamics of heparin in the treatment of AHR and

172 the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-cl

173 The pharmacodynamics of inhaled heparin are however transien

174 safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rh

175 e assessed the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation a

176 to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children aged 2-5 years

177 less, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be u

178 ed dose (MTD), safety, pharmacokinetics, and pharmacodynamics of LCL161 in patients with advanced sol

179 g analysis was done to better understand the pharmacodynamics of Lithium by isolating the norepinephr

180 The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the mos

181 The safety, pharmacokinetics, and pharmacodynamics of MMV390048 support its further develo

182 This new insight into the pharmacodynamics of mTOR inhibitors in regulation of neu

183 to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001, NCT028682

184 ercellular drug transfer that contributes to pharmacodynamics of neighboring cells.

185 idine deaminase, on the pharmacokinetics and pharmacodynamics of oral DAC were evaluated in mice and

186 roteins involved in the pharmacokinetics and pharmacodynamics of rasagiline, and genes previously ass

187 safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501).

188 significantly improved pharmacokinetics and pharmacodynamics of repeated mATG administration.

189 ndary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in this combination and

190 acterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor of

191 taken by analysing the pharmacokinetics and pharmacodynamics of single doses of subcutaneous aldesle

192 efined as the day of injection, and thus the pharmacodynamics of single injections could be assessed;

193 models incorporate the pharmacokinetics and pharmacodynamics of the antibiotics, the innate and adap

194 ed dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with ref

195 d to reflect pharmacological action and thus pharmacodynamics of the delivered enzyme.

196 nteractions and altered pharmacokinetics and pharmacodynamics of the different antihypertensive medic

197 pairs motor performance concomitant with the pharmacodynamics of the drug, but also impairs future mo

198 te understanding of the pharmacokinetics and pharmacodynamics of the drugs.

199 We review the pharmacokinetics and pharmacodynamics of the pediatric procedural sedation ph

200 We assessed the safety and pharmacodynamics of the vaccine in patients with coeliac

201 mechanisms of action of antibiotics and the pharmacodynamics of their interaction with bacteria tell

202 emporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs.

203 ient differences in the pharmacokinetics and pharmacodynamics of these medications.

204 BIO 300 and a reasonable illustration of the pharmacodynamics of this radiation countermeasure.

205 The pharmacokinetics and pharmacodynamics of ticagrelor 60 mg bid have not been s

206 safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with JNJ-42165279 in subje

207 mulations and to characterize the safety and pharmacodynamics of triamcinolone acetonide (TA) deliver

208 sed the safety, tolerability, adherence, and pharmacodynamics of two doses of NaHCO(3) over 28 weeks

209 absorption, excretion, pharmacokinetics, and pharmacodynamics of various anticoagulants.

210 The pharmacodynamics of voriconazole against wild-type and 3

211 harmacokinetics) and the biological effects (pharmacodynamics) of the chemical on the organism.

212 results in altered drug pharmacokinetics and pharmacodynamics or formation of toxic metabolites which

213 Pharmacodynamics outcomes were modeled using a Bayesian

214 of different genetic variants on clopidogrel pharmacodynamics over time in patients undergoing PCI.

215 e used to assess furosemide pharmacokinetics/pharmacodynamics parameters.

216 armacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon-stimulated gene

217 ween plasma pharmacokinetics (PK), tumor PK, pharmacodynamics (PD) (client protein degradation), tumo

218 Compound 12 was evaluated in a mouse pharmacodynamics (PD) model and demonstrated a 56% incre

219 stemic and mucosal pharmacokinetics (PK) and pharmacodynamics (PD) of 2F5 IgG and 2F5 Fab fragments w

220 ffect of smoking on the pharmacokinetics and pharmacodynamics (PD) of clopidogrel and prasugrel thera

221 se as a whole, and evaluated the single-cell pharmacodynamics (PD) of Ptx (by in vivo PD microscopy).

222 ty, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of rontalizumab, a humanized IgG1

223 ty, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the human anti-C5 monoclonal an

224 itiating hydroxyurea therapy, to investigate pharmacodynamics (PD) parameters, including HbF response

225 ET and assess the pharmacokinetics (PK) and pharmacodynamics (PD) profile of OA.

226 ety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-0056

227 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of KRN23 follo

228 evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic acti

229 An understanding of pharmacokinetics (PK), pharmacodynamics (PD), antimicrobial susceptibility test

230 s study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical efficacy and safety of e

231 imum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib

232 cogenetics, including pharmacokinetics (PK), pharmacodynamics (PD), gene and pathway interactions, an

233 ion affecting drug pharmacokinetics (PK) and pharmacodynamics (PD).

234 bes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and terato

235 usceptibility to an antibacterial agent (ie, pharmacodynamics [PD]), is a given; however, drug exposu

236 rmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]).

237 Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) performed in animals are often no

238 tment and follow-up and were included in the pharmacodynamics, pharmacokinetics, and safety analyses.

239 The study assessed the pharmacodynamics, pharmacokinetics, and safety of BMS-66

240 the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies

241 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy

242 We discuss the pharmacodynamics, pharmacokinetics, toxic effects, and c

243 sure, determined by the pharmacokinetics and pharmacodynamics (PK/PD) after intravenous (IV) antibiot

244 Here we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to rationally develop

245 ategies, such as population pharmacokinetics/pharmacodynamics (PK/PD) and systems biology/pharmacolog

246 -TB) is designed to perform pharmacokinetics/pharmacodynamics (PK/PD) experiments, and hence the desi

247 arge number of tuberculosis pharmacokinetics/pharmacodynamics (PK/PD) studies that have not been subj

248 on was driven by a modified pharmacokinetics-pharmacodynamics (PK/PD)-based dosing approach.

249 To determine the pharmacokinetics and pharmacodynamics (PKPD) of ciprofloxacin prophylaxis in

250 idered, including viral pharmacokinetics and pharmacodynamics, potential toxic effects, and monitorin

251 bitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due

252 In addition, pharmacokinetics/pharmacodynamics profile in serum and lung tissue showed

253 sign of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwante

254 ay, in part, be parkin-independent or to the pharmacodynamics properties of nilotinib.

255 tically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier

256 lyglutamine-expanded proteins as well as the pharmacodynamics readouts to monitor their efficacy in p

257 to analyze the in vivo pharmacokinetics and pharmacodynamics relationship of KDM1A inhibitors, as ha

258 tered pharmacokinetics (p < 0.01), a reduced pharmacodynamics response to furosemide also became impo

259 aluation Criteria in Solid Tumors) response, pharmacodynamics, RET mutational status, and biomarker a

260 of testing issues, murine and human in vivo pharmacodynamics, safety of off-label doses, and treatme

261 le, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide

262 We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an

263 l evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissu

264 were estimated through pharmacokinetics and pharmacodynamics simulation, IFE outcome was best predic

265 are not a unidirectional influence on opioid pharmacodynamics, since TLR4(-/-) mice had reduced oxyco

266 Human pharmacokinetics/pharmacodynamics studies confirmed this link between mic

267 al evolution in patients on optimal therapy, pharmacodynamics studies explaining the extraordinarily

268 ry-based timolol release studies and in vivo pharmacodynamics studies in beagle dogs to evaluate the

269 Exploratory pharmacodynamics studies including changes in diffusion-

270 tigation of kinetic mechanisms in disease or pharmacodynamics studies using MS data from longitudinal

271 cokinetic analyses, in vivo pharmacokinetics/pharmacodynamics studies, and maximum-tolerated-dose stu

272 ristic drug, SAL, during pharmacokinetic and pharmacodynamics studies.

273 on, including a comparative pharmacokinetics/pharmacodynamics study that is usually conducted in heal

274 ive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomy

275 rated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully predicted effects of exoso

276 ical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosin

277 Pharmacodynamics suggested that a single dose of oritava

278 physical function, frailty, disability, and pharmacodynamics that all merit further investigation.

279 w previously unappreciated complex nonlinear pharmacodynamics that determine their inhibitory potenti

280 of fMRI affords detailed mapping of regional pharmacodynamics that underlie mechanisms of pain suppre

281 orating viral dynamics and pharmacokinetics/ pharmacodynamics to assess how suboptimal adherence affe

282 ing of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneou

283 h vein injection, and exhibited the expected pharmacodynamics to remove uric acid in hyperuricemic bl

284 We compare the pharmacokinetics and pharmacodynamics to the clinical comparator progesterone

285 This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of

286 Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinical outcomes sugges

287 macology relies on ligands that change their pharmacodynamics upon photoisomerization.

288 -miR, which is more robust than conventional pharmacodynamics using downstream target gene derepressi

289 formulation is a major factor in optimizing pharmacodynamics using this technique.

290 Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite rigorous exclusion

291 Combining models of drug pharmacokinetics, pharmacodynamics, viral kinetics and symptom dynamics, w

292 Pharmacodynamics were assessed by measuring the ability

293 Pharmacokinetics and pharmacodynamics were assessed on days 9 and 10.

294 Pharmacokinetics, immunogenicity, and pharmacodynamics were evaluated, and disease activity wa

295 ures and pharmacokinetics were assessed, and pharmacodynamics were measured in blood, hair follicles,

296 Efficacy and pharmacodynamics were secondary end points.

297 , with greatly improved pharmacokinetics and pharmacodynamics when compared with recombinant IL-2 to

298 nt altered indomethacin pharmacokinetics and pharmacodynamics, which is probably the result of reduce

299 the RTB carrier may support distinct in vivo pharmacodynamics with potential to address hard-to-treat

300 edisposition to altered pharmacokinetics and pharmacodynamics with resulting increased risk of toxici